Has Nedim Ruhotina, MD received payments from drug or device companies?

Yes. Drug and device makers reported $275,443 in general payments to Nedim Ruhotina, MD across 403 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nedim Ruhotina, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nedim Ruhotina, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nedim Ruhotina, MD

Urology · Liverpool, NYNPI 1811288954

Payments from drug & device makers

$275,443in general payments, 2019–2025

Across 403 payments — averaging $683.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Palette Life Sciences, Inc.$201K
Teleflex LLC$49K
Johnson & Johnson$6K
Bayer$5K
Bioprotect Medical, Inc.$4K
Janssen Scientific Affairs, LLC$4K
plus $7K from 37 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Palette Life Sciences, Inc.	33	$200,734
Teleflex LLC	30	$48,983
Johnson & Johnson(2 entities)	31	$6,175
Bayer	17	$5,038
Bioprotect Medical, Inc.	6	$4,032
Janssen Scientific Affairs, LLC	14	$3,795
Astellas Pharma US Inc	58	$1,184
Dendreon Pharmaceuticals LLC	33	$1,077
Axonics, Inc.	33	$543
Novartis	5	$320
Pfizer	16	$308
Coloplast	15	$289
AstraZeneca	11	$276
Ferring Pharmaceuticals Inc.	7	$214
Boston Scientific	9	$213
Immunitybio, Inc.	2	$191
Sumitomo Pharma America, Inc.	9	$189
Medtronic(2 entities)	10	$181
AbbVie	9	$174
Urogen Pharma, Inc.	4	$163
Histosonics, Inc.	1	$142
Accord Healthcare, Inc.	3	$139
Procept Biorobotics Corporation	1	$136
Tolmar Pharmaceuticals, Inc.	5	$108
Merck	5	$103
Telix Pharmaceuticals	5	$98
Urovant Sciences Inc	4	$88
Neotract Inc.	2	$72
Endo Pharmaceuticals Inc.	3	$59
Antares Pharma, Inc.	3	$55
180 Medical, Inc.	3	$50
Amgen	3	$47
Olympus America Inc.	2	$40
Sun Pharmaceutical Industries Inc.	2	$34
Blue Earth Diagnostics	1	$30
Laborie Medical Technologies Corp.	1	$30
Progenics Pharmaceuticals, Inc.	1	$24
Tolmar, Inc.	1	$23
Myovant Sciences Inc.	1	$20
Verity Pharmaceuticals Inc.	1	$18
Alnylam Pharmaceuticals Inc.	1	$18
Myriad Genetic Laboratories, Inc.	1	$16
Clarus Therapeutics Inc.	1	$14

How this compares

$275,443 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.

See all urology providers in New York →

Medicare billing

Part B allowed, 2024

$761,460

Medicare patients

879

Services billed

14,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urology in Liverpool

Christopher PieczonkaSyracuse$31.2M
Guarionex DecastroNew York$5.7M
Mitchell EfrosGarden City$4.2M
James McKiernanNew York$4.1M
William HuangNew York$3.9M
Jed KaminetskyMiddle Village$3.5M
Evan GoldfischerPoughkeepsie$3.1M
Gennady BratslavskySyracuse$2.5M
Ashutosh TewariNew York$2.5M
Manish ViraNew Hyde Park$2.1M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →